Involvement of Carboxylesterase 1 and 2 in the Hydrolysis of Mycophenolate Mofetil
Authors:
- Masatomo MiuraMMMasatomo Miura
- Shoutaro KatoSKShoutaro Kato
- Tomomichi SoneTSTomomichi Sone
- Masakazu IsobeMIMasakazu Isobe
- Shigeru SatohSSShigeru Satoh
- 1 December 2010
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (12) , 2210-2217
Abstract
Mycophenolate mofetil (MMF) is the ester prodrug of the immunosuppressant agent mycophenolic acid (MPA) and is rapidly activated by esterases after oral administration. However, the role of isoenzymes in MMF hydrolysis remains unclear. Although human plasma, erythrocytes, and whole blood contain MMF hydrolytic activities, the mean half-lives of MMF in vitro were 15.1, 1.58, and 3.20 h, respectively. Thus, blood esterases seemed to contribute little to the rapid MMF disappearance in vivo. In vitro analyses showed that human intestinal microsomes exposed to 5 and 10 μM MMF exhibited hydrolytic activities of 2.38 and 4.62 nmol/(min · mg protein), respectively. Human liver microsomes exhibited hydrolytic activities of 14.0 and 26.1 nmol/(min · mg protein), respectively, approximately 6-fold higher than those observed for intestinal microsomes. MMF hydrolytic activities in human liver cytosols were 1.40 and 3.04 nmol/(min · mg protein), respectively. Because hepatic cytosols generally contain 5-fold more protein than microsomes, MMF hydrolysis in human liver cytosols corresponded to approximately 50% of that observed in microsomes. Fractions obtained by 9000g centrifugation of supernatants from COS-1 cells expressing human carboxylesterase (CES) 1 or 2 exhibited MMF hydrolytic activity, with CES1-containing fractions showing higher catalytic efficiency than CES2-containing fractions. The CES inhibitor bis-p-nitrophenylphosphate inhibited MMF hydrolysis in human liver microsomes and cytosols with IC50 values of 0.51 and 0.36 μM, respectively. In conclusion, both intestinal and hepatic CESs and in particular CES1 may be involved in MMF hydrolysis and play important roles in MMF bioactivation. Hepatic CES1 activity levels may help explain the between-subject variability observed for MMF usage.Keywords
This publication has 25 references indexed in Scilit:
- Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipientsXenobiotica, 2009
- C-440T/T-331C Polymorphisms in theUGT1A9Gene Affect the Pharmacokinetics of Mycophenolic Acid in Kidney TransplantationPharmacogenomics, 2007
- The impact of uridine diphosphate–glucuronosyltransferase 1A9 () gene promoter region single-nucleotide polymorphisms and on early mycophenolic acid dose-interval exposure in de novo renal allograft recipientsClinical Pharmacology & Therapeutics, 2005
- Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant RecipientsTherapeutic Drug Monitoring, 2005
- THE MAIN ROLE OF UGT1A9 IN THE HEPATIC METABOLISM OF MYCOPHENOLIC ACID AND THE EFFECTS OF NATURALLY OCCURRING VARIANTSDrug Metabolism and Disposition, 2004
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous AdministrationThe Journal of Clinical Pharmacology, 1996
- Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate MofetilImmunological Reviews, 1993
- Identification and partial purification of the major aspirin hydrolyzing enzyme in human bloodArthritis & Rheumatism, 1983
- Phosphorsäur e-bis-[p-nitro-phenylester], ein neuer Hemmstoff mikrosomaler CarboxylesterasenHoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1967